#Sweden #Stockholm #Leqembi #BioArctic #Alzheimer’s treatment

Overview of BioArctic's Q3 2025 Report

On November 13, 2025, BioArctic AB released its interim report covering the third quarter of the year, highlighting substantial developments in its treatment portfolio of neurodegenerative diseases, particularly Alzheimer's disease.

Major Developments

During this period, BioArctic made remarkable strides not only in its primary Alzheimer's treatment, Leqembi (lecanemab), but also through strategic partnerships aimed at expanding its therapeutic offerings.

One of the key highlights was the presentation of new data on lecanemab at the AAIC Congress. This research emphasized the long-term efficacy, safety, and the drug’s potential through subcutaneous dosing, which is a significant advancement in treatment methodologies.

Furthermore, the company signed a collaboration and licensing agreement with Novartis, worth USD 30 million upfront. This partnership promises to integrate BioArctic’s proprietary BrainTransporter technology with Novartis’ proprietary antibody, aiming for more effective treatments in neurodegeneration.

Leqembi's Approval and Sales Growth

Leqembi has gained traction globally, with recent approvals expanding its availability in regions such as Australia, Bahrain, India, and parts of the Middle East and Europe. The latest update includes the FDA's approval for the weekly subcutaneous maintenance treatment of Leqembi, setting the stage for a broader rollout.

Sales figures for the quarter showed net revenues of SEK 133.3 million, primarily driven by royalties from Leqembi. The product has shown consistent growth, revealing a 14% increase quarter-on-quarter when adjusted for specific market effects, such as stocking in China.

Financial Insights

Despite facing operating losses of SEK 28.8 million and a total deficit of SEK 86.9 million for the quarter, the overall cash and investments at the end of September reached SEK 1.882 billion, a strong position for future investments and operations.

CEO Gunilla Osswald noted the continuing need for innovative treatments to tackle Alzheimer’s disease and expressed optimism regarding both Leqembi’s trajectory and the promising pipeline of projects poised for development.

Looking Ahead: Expanding Horizons

Following the quarter, BioArctic celebrated its first patient treated with Leqembi in Finland, alongside its strategies to strengthen its presence in Nordic markets. The company also announced further advancements in its research pipeline, signaling a proactive approach to addressing various neurodegenerative disorders, including Huntington's disease and progressive stages of Alzheimer’s.

The firm is gearing up for phase 2 studies that will begin to reveal results in late 2026, focusing on the application of the BrainTransporter technology in developing potential treatment modalities. This could provide new avenues for addressing complex conditions such as Huntington’s, which currently lacks disease-altering therapies.

BioArctic's commitment to forging ahead with both existing and new initiatives outlines its dedication to driving innovative solutions within the healthcare sector.

In conclusion, the achievements and strategic partnerships highlighted within the Q3 report not only reflect BioArctic’s commitment to combating neurodegenerative diseases but also reaffirm the company’s role as a key player in the pharmaceutical landscape.

For additional information and ongoing updates, stakeholders are encouraged to participate in the company’s upcoming audiocast presentation, where executives will discuss these developments and future prospects in greater detail.